Skip to main content
SpringerLink
Log in

Prognosis

  • Chapter
  • First Online:
Male Breast Cancer

Abstract

When properly matched for stage age and co-morbidity the prognosis of MBC and FBC is similar. Because MBC patients are older and often have more co-morbidity than FBC cases, overall survival may be worse but cancer-specific survival is similar. Ethnic differences in outcome are cultural and economic but not genetic. Hierarchical clustering indicates that best survival is exhibited by luminal B1.1 group and the worst by luminal A. BRCA2 mutation carriers have a worse prognosis than that of sporadic cases. Oncotype Dx™ may be useful in determining recurrence risk and selected of appropriate adjuvant systemic therapy. Over-expression of both HIF-1a and plasminogen activator inhibitor 1 (PAI-1) have been shown on separate multivariate analyses to be significant prognostic variables. In contrast MBC tumours over-expressing TAZ/CTGF and YAP/CTGF carried a worse prognosis. Prognostic models developed for FBC cases can also be of value in MBC.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Mausner JS, Shimkin MB, Moss NH, Rosemond GP. Cancer of the breast in Philadelphia Hospitals 1951-1964. Cancer. 1969;23:262–74.

    Article  Google Scholar 

  2. Levi F, Randimbison L, La Vecchia C. Breast cancer survival in relation to sex and age. Oncology. 1992;49:413–7.

    Article  CAS  PubMed  Google Scholar 

  3. Willsher PC, Leach IH, Ellis IO, Bourke JB, Blamey RW, Robertson JF. A comparison outcome of male breast cancer with female breast cancer. Am J Surg. 1997;173:185–8.

    Article  CAS  PubMed  Google Scholar 

  4. Scott-Conner CE, Jochimsen PR, Menck HR, Winchester DJ. An analysis of male and female breast cancer treatment and survival among demographically identical pairs of patients. Surgery. 1999;126:775–80.

    Article  CAS  PubMed  Google Scholar 

  5. Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN. Breast carcinoma in men. A population-based study. Cancer. 2004;101:51–7.

    Article  PubMed  Google Scholar 

  6. El-Tamer MB, Komenaka IK, Troxel A, Li H, Joseph K-A, et al. Men with breast cancer have better disease-specific survival than women. Arch Surg. 2004;139:1079–82.

    Article  PubMed  Google Scholar 

  7. Anan K, Mitsuyama S, Nishihara K, Abe Y, Iwashita T, et al. Breast cancer in Japanese men: does sex affect prognosis? Breast Cancer. 2004;11:180–6.

    Article  PubMed  Google Scholar 

  8. Macdonald G, Paltiel C, Olivotto IA, Tyldesley S. A comparative analysis of radiotherapy use and patient outcome in males and females with breast cancer. Ann Oncol. 2005;16:1442–8.

    Article  CAS  PubMed  Google Scholar 

  9. Nahleh ZA, Srikantiah R, Safa M, Jazieh AR, Muhleman A, Komrokji R. Male breast cancer in the Veterans Affairs population a comparative analysis. Cancer. 2007;109:1471–7.

    Article  PubMed  Google Scholar 

  10. Marchal F, Salou M, Marchal C, Lesur A, Desandes E. Men with breast cancer have same disease-specific and event-free survival as women. Ann Surg Oncol. 2009;16:972–8.

    Article  PubMed  Google Scholar 

  11. Anderson WF, Jatoi I, Tse J, Rosenberg PS. Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol. 2010;28:232–9.

    Article  PubMed  Google Scholar 

  12. Foerster R, Foerster FG, Wulff V, Schubotz B, Baaske D, et al. Matched-pair analysis of patients with female and male breast cancer: a comparative analysis. BMC Cancer. 2011;11:335–43.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Nilsson C, Holmqvist M, Bergkvist L, Hedenfalk I, Lambe M, Fjällskog M-L. Similarities and differences in the characteristics and primary treatment of breast cancer in men and women – a population based study (Sweden). Acta Oncol. 2011;50:1083–8.

    Article  PubMed  Google Scholar 

  14. Shaaban AM, Ball GR, Brannan RA, Cserni G, Di Benedetto A, et al. A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences. Breast Cancer Res Treat. 2012;133:949–58.

    Article  CAS  PubMed  Google Scholar 

  15. Chen X, Liu X, Zhang L, Li S, Shi Y, Tong Z. Poorer survival of male breast cancer compared with female breast cancer patients may be due to biological differences. Jpn J Clin Oncol. 2013;43:954–63.

    Article  PubMed  Google Scholar 

  16. Kwong A, Chau WW, Mang OW, Wong CH, Suen DT, et al. Male breast cancer: a population-based comparison with female breast cancer in Hong Kong, southern china: 1997-2006. Ann Surg Oncol. 2014;21:1246–53.

    Article  PubMed  Google Scholar 

  17. Iorfida M, Bagnardi V, Rotmensz N, Munzone E, Bonanni B, et al. Outcome of male breast cancer: a matched single-institution series. Clin Breast Cancer. 2014;14:371–7.

    Article  PubMed  Google Scholar 

  18. Yu X-F, Yang H-J, Yu Y, Zou D-H, Miao LL. A prognostic analysis of male breast cancer (MBC) compared with post-menopausal female breast cancer (FBC). PLoS ONE. 2015 Aug 27;10(8):e0136670. doi:10.1371/journal.pone.0136670.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Yu E, Stitt L, Ujovic O, Joseph K, Assouline A, et al. Prognostic factors for male breast cancer: similarity to female counterparts. Anticancer Res. 2013;33:2227–32.

    CAS  PubMed  Google Scholar 

  20. Choi MY, Lee SK, Lee JE, Park HS, Lim ST, et al. Characterization of Korean male breast cancer using an online nationwide breast-cancer database: matched-pair analysis of patients with female breast cancer. Medicine (Baltimore). 2016;95(16):e3299.

    Article  Google Scholar 

  21. Adami HO, Hakulinen T, Ewertz M, Tretli S, Holmberg L, Karjalainen S. The survival pattern in male breast cancer. An analysis of 1429 patients from the Nordic countries. Cancer. 1989;64:1177–82.

    Article  CAS  PubMed  Google Scholar 

  22. Gough DB, Donohue JH, Evans MM, Pernicone PJ, Wold LE, et al. A 50-year experience of male breast cancer: is outcome changing? Surg Oncol. 1993;2:325–33.

    Article  CAS  PubMed  Google Scholar 

  23. Ioka A, Tsukuma H, Ajiki W, Oshima A. Survival of male breast cancer patients: a population-based study in Osaka, Japan. Jpn J Clin Oncol. 2006;36:699–703.

    Article  PubMed  Google Scholar 

  24. Tural D, Selcukbiricik F, Aydogan F, Bese N, Yetmen O. Male breast cancers behave differently in elderly patients. Jpn J Clin Oncol. 2013;3:22–7.

    Article  Google Scholar 

  25. Sineshaw HM, Freedman RA, Ward EM, Flanders WD, Jemal A. Black/white disparities in receipt of treatment and survival among men with early-stage breast cancer. J Clin Oncol. 2015;33:2337–44.

    Article  PubMed  Google Scholar 

  26. Shahraki HR, Salehi A, Zare N. Survival prognostic factors of male breast cancer in Southern Iran: a LASSO-Cox regression approach. Asian Pac J Cancer Prev. 2015;16:6773–7.

    Article  PubMed  Google Scholar 

  27. Flaherty DC, Bawa R, Burton C. Breast cancer in male adolescents and young adults. Ann Surg Oncol. 2017;24(1):84–90.

    Article  PubMed  Google Scholar 

  28. Leone JP, Zwenger AO, Iturbe J, Leone J, Leone BA, et al. Prognostic factors in male breast cancer: a population-based study. Breast Cancer Res Treat. 2016;156(3):539–48.

    Article  PubMed  Google Scholar 

  29. Adekolujo OS, Tadisina S, Koduru U, Gernand J, Smith SJ, Kakarala RR. Impact of marital status on tumor stage at diagnosis and on survival in male breast cancer. Am J Mens Health. 2016. pii: 1557988316669044. [Epub ahead of print]

    Google Scholar 

  30. Keller AZ. Demographic, clinical and survivorship characteristics of males with primary cancer of the breast. Am J Epidemiol. 1967;85:185–99.

    Article  Google Scholar 

  31. Brenner B, Fried G, Levitzki P, Rakowsky E, Lurie H, et al. Male breast carcinoma in Israel. Higher incidence but possibly better prognosis in Ashkenazi Jews. Cancer. 2002;94:2128–33.

    Article  PubMed  Google Scholar 

  32. O’Malley CD, Prehn AW, Shema SJ, Glaser SL. Racial/ethnic differences in survival rates in a population-based series of men with breast carcinoma. Cancer. 2002;94:2836–43.

    Article  PubMed  Google Scholar 

  33. Crew KD, Neugut AI, Wang X, Jacobson JS, Grann VR. Racial disparities in treatment and survival of male breast cancer. J Clin Oncol. 2007;25:1089–98.

    Article  PubMed  Google Scholar 

  34. O’Brien B, Koru-Sengul T, Miao F, Saclarides C, et al. Disparities in overall survival for male breast cancer patients in the State of Florida (1996-2007). Clin Breast Cancer. 2015;15:177–87.

    Article  Google Scholar 

  35. Shi R, Taylor H, Liu L, Mills G, Burton G. Private payer’s status improves male breast cancer survival. Breast J. 2015;28 doi:10.1111/tbj.12523. [Epub ahead of print].

  36. Rayson D, Erlichman C, Suman VJ, Roche PC, Wold LE, et al. Molecular markers in male breast carcinoma. Cancer. 1998;83:1947–55.

    Article  CAS  PubMed  Google Scholar 

  37. Wang-Rodriguez J, Cross K, Gallagher S, Djahanban M, Armstrong JM, et al. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases. Mod Pathol. 2002;15:853–61.

    Article  PubMed  Google Scholar 

  38. Sørlie T, Perou CM, Tibshirani R, Aas T, Geislerg S, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS. 2001;98:10869–74.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Nilsson C, Johansson I, Ahlin C, Thorstenson S. Molecular subtyping of male breast cancer using alternative definitions and its prognostic impact. Acta Oncol. 2013a;52:102–9.

    Article  PubMed  Google Scholar 

  40. Ge Y, Sneige N, Eltorky MA, Wang Z, Lin E, et al. Immunohistochemical characterization of subtypes of male breast carcinoma. Breast Cancer Res. 2009;11:R28. doi:10.1186/bcr2258.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Kanthan R, Fried I, Rueckl T, Senger JL, Kanthan SC. Expression of cell cycle proteins in male breast carcinoma. World J Surg Oncol. 2010;8:10–20.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Nilsson C, Koliadi A, Johansson I, Ahlin C, Thorstenson S, et al. High proliferation is associated with inferior outcome in male breast cancer patients. Mod Pathol. 2013b;26:87–94.

    Article  CAS  PubMed  Google Scholar 

  43. Schildhaus HU, Schroeder L, Merkelbach-Bruse S, Binot E, et al. Therapeutic strategies in male breast cancer: clinical implications of chromosome 17 gene alterations and molecular subtypes. Breast. 2013;22:1066–71.

    Article  PubMed  Google Scholar 

  44. Abreu MH, Afonso N, Abreu PH, Menezes F, Lopes P, et al. Male breast cancer: Looking for better prognostic subgroups. Breast. 2016;26:18–24.

    Article  PubMed  Google Scholar 

  45. Arslan UY, Oksüzoğlu B, Ozdemir N, Aksoy S, Alkış N, et al. Outcome of non-metastatic male breast cancer: 118 patients. Med Oncol. 2012;29:554–60.

    Article  PubMed  Google Scholar 

  46. Kornegoor R, Verschuur-Maes AH, Buerger H, Hogenes MC, et al. Immunophenotyping of male breast cancer. Histopathology. 2012a;61:1145–55.

    Article  PubMed  Google Scholar 

  47. Ottini L, Silvestri V, Rizzolo P, Falchetti M, Zanna I, et al. Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: results from a collaborative multicenter study in Italy. Breast Cancer Res Treat. 2012a;134:411–8.

    Article  CAS  PubMed  Google Scholar 

  48. Aggarwal A, Liu ML, Krasnow SH. Breast cancer in male veteran population: an analysis from VA cancer registry. J Commun Supp Oncol. 2014;12:293–7.

    Article  Google Scholar 

  49. Gogia A, Raina V, Deo S, Shukla NK, Mohanti BK. Male breast cancer: a single institute experience. Indian J Cancer. 2015;52:526–9.

    Article  CAS  PubMed  Google Scholar 

  50. Gargiulo P, Pensabene M, Milano M, Arpino G, Giuliano M, et al. Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis. BMC Cancer. 2016;16:375–85.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Blin N, Kardaś I, Welter C, Ryś J, Niezabitowski A, et al. Expression of the c-erbB2 proto-oncogene in male breast carcinoma: lack of prognostic significance. Oncology. 1993;50:408–411. Bloom KJ, Govil H, Gattuso P, Reddy V, Francescatti D. Status of HER-2 in male and female breast carcinoma. Am J Surg. 2001;182:389–92.

    Google Scholar 

  52. Bloom KJ, Govil H, Gattuso P, Reddy V, Francescatti D. Status of HER-2 in male and female breast carcinoma. Am J Surg. 2001;182:389–92.

    Article  CAS  PubMed  Google Scholar 

  53. Bärlund M, Kuukasjärvi T, Syrjäkoski K, Auvinen A, Kallioniemi A. Frequent amplification and overexpression of CCND1 in male breast cancer. Int J Cancer. 2004;111:968–71.

    Article  PubMed  Google Scholar 

  54. Paik S, Shak S, Tang G, Kim H, Baker J, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817–26.

    Article  CAS  PubMed  Google Scholar 

  55. Kiluk JV, Lee MC, Park CK, Meade T, Minton S, et al. Male breast cancer: management and follow-up recommendations. Breast J. 2011;17:503–9.

    Article  PubMed  Google Scholar 

  56. Yokoyama J, Kobayashi T, Nakamura T, Nakajima Y. A case of male breast cancer in which oncotype DX was used to determine the therapeutic strategy. Gan To Kagaku Ryoho. 2012;39:2057–9.

    PubMed  Google Scholar 

  57. Grenader T, Yerushalmi R, Tokar M, Fried G, Kaufman B, et al. The 21-gene recurrence score assay (Oncotype DX™) in estrogen receptor-positive male breast cancer: experience in an Israeli cohort. Oncology. 2014;87:1–6.

    Article  CAS  PubMed  Google Scholar 

  58. Kwiatkowska E, Teresiak M, Filas V, Karczewska A, Breborowicz D, Mackiewicz A. BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients. Clin Cancer Res. 2003;9:4452–9.

    CAS  PubMed  Google Scholar 

  59. Johansson I, Nilsson C, Berglund P, Strand C, et al. High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer. Breast Cancer Res Treat. 2011;129:747–60.

    Article  PubMed  Google Scholar 

  60. Johansson I, Laussa M, Holm K, Staaf J, Nilsson C, et al. Genome methylation patterns in male breast cancer – Identification of an epitype with hypermethylation of polycomb target genes. Mol Oncol. 2015;9:1565–79.

    Article  CAS  PubMed  Google Scholar 

  61. Tan EY, Yan M, Campo L, Han C, Takano E, et al. The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. Br J Cancer. 2009;100:405–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Kornegoor R, Verschuur-Maes AHJ, Buerger H, Hogenes MCH, de Bruin PC, et al. Fibrotic focus and hypoxia in male breast cancer. Mod Pathol. 2012b;25:1397–404.

    Article  CAS  PubMed  Google Scholar 

  63. Deb S, Johansson I, Byrne D, Nilsson C, Constable L, et al. Nuclear HIF1A expression is strongly prognostic in sporadic but not familial male breast cancer. Mod Pathol. 2014;27(9):1223–30. doi:10.1038/modpathol.2013.231.

    Article  CAS  PubMed  Google Scholar 

  64. Voduc D, Cheang M, Nielsen T. GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value. Cancer Epidemiol Biomark Prev. 2008;17:365–73.

    Article  CAS  Google Scholar 

  65. Gonzalez RS, Wang J, Kraus T, Sullivan H, Adams AL, Cohen C. GATA-3 expression in male and female breast cancers: comparison of clinicopathologic parameters and prognostic relevance. Hum Pathol. 2013;44:1065–70.

    Article  CAS  PubMed  Google Scholar 

  66. Moredo Anelli TF, Brentani MM, Torloni H, Ribeiro KCB, Nonogaki S, Brentani RR. Overexpression of plasminogen activator in male breast cancer. Clin Breast Cancer. 2001;2:156–7.

    Article  CAS  PubMed  Google Scholar 

  67. Meijer-van Gelder ME, Look MP, Bolt-de Vries J, Peters HA, Klijn JG, Foekens JA. Clinical relevance of biologic factors in male breast cancer. Breast Cancer Res Treat. 2001;68:249–60.

    Article  CAS  PubMed  Google Scholar 

  68. Pinto R, De Summa S, Danza K, Popescu O, Paradiso A, et al. MicroRNA expression profiling in male and female familial breast cancer. Br J Cancer. 2014;111:2361–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Di Benedetto A, Mottolese M, Sperati F, Ercolani C, Di Lauro L, et al. The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer. Oncotargets. 2016;7:43188–98.

    Google Scholar 

  70. Millican-Slater RA, Sayers CD, Hanby AM, Hughes TA. Expression of phosphorylated eIF4E–binding protein 1, but not of eIF4E itself, predicts survival in male breast cancer. Br J Cancer. 2016;115:339–45. doi:10.1038/bjc.2016.178. [Epub ahead of print].

  71. van der Pol CC, Lacle MM, Witkamp AJ, Kornegoor R, Miao H, et al. Prognostic models in male breast cancer. Breast Cancer Res Treat. 2016;160:339–46.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Research Oncology, Guy’s Hospital, London, United Kingdom

    Ian Fentiman

Authors
  1. Ian Fentiman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Fentiman, I. (2017). Prognosis. In: Male Breast Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-04669-3_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-04669-3_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-04668-6

  • Online ISBN: 978-3-319-04669-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation